Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer

Zhou, Tong; Zhang, Guangjun; Liu, Zuoliang; Xia, Shu-Sen; Tian, Hongpeng

doi:10.1007/s00384-012-1528-1

Cited by 92 publications

(79 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of importance, miR-92a was upregulated in LARC specimens and correlated inversely with the expression levels of its putative targets IQGAP2 and KLF4. These findings are consistent with previous work suggesting an oncogenic role of miR-92a in colorectal cancer (CRC) (Tsuchida et al, 2011;Yamada et al, 2013;Zhou et al, 2013).…”

Section: To the Editorsupporting

confidence: 94%

Deregulation of miR‐92a in locally advanced rectal cancer

Cristóbal

Torrejón

Madoz‐Gúrpide

et al. 2016

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

show abstract

Section: To the Editorsupporting

confidence: 94%

Deregulation of miR‐92a in locally advanced rectal cancer

Cristóbal

Torrejón

Madoz‐Gúrpide

et al. 2016

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

show abstract

“…In a study recruited 40 colorectal adenocarcinoma patients and 40 control subjects, expression levels of serum miR-21 were measured using qRT-PCR assay, the results showed high expression level of serum miR-21 was associated with high clinical stages in the patients. Similar results were found in miR-29a in a study recruited 100 sera of patients with CRC and 30 sera of healthy donors [37]. Some miRNAs can distinguish TNM stage in CRC tissue samples, but failed in circulating miRNAs.…”

Section: Circulating Mirnas In Tnm Stagesupporting

confidence: 71%

Circulating MicroRNAs in Colorectal Cancer

Huang¹,

Ge²,

Hu³

et al. 2017

J Mol Genet Med

View full text Add to dashboard Cite

IntroductionWith increasing incidence, colorectal cancer (CRC) remains the second most common cancer in women and the third in men, despite the improved screening techniques, most patients diagnosed CRC are at late stage, CRC is the second leading cause of cancer-related death worldwide [1]. Complete tumor resection by surgery is the main therapeutic modality, it was reported that 5-year survival rates were in range from 93.2% for the earliest stage to 6.6% for advanced disease at diagnosis according to Duke's stage. So, good prognosis of CRC is linked to stage at earlier diagnosis. However, due to asymptomatic in early stage of CRC, many cases were detected at late stage. In clinical practice, colonoscopy is used in the diagnosis and treatment of CRC, but has not yet been wide-used as a screening tool because of some limitations, such as the requirements of bowel preparation, cost burden and perforation risk [2]. In addition, fecal occult blood test (FOBT), some convenient circulating blood biomarkers, including the most frequently used marker carcinoembryonic antigen (CEA), carbohydrate antigens, CA125, CA153 and CA199, are lack of sufficient sensitivity or specificity. For example, the specificity of FOBT is about 95%, while the sensitivity of is around 70% to 75% [3], the sensitivity and specificity of CEA is 60% and 34%, respectively [4]. Therefore, new strategies and novel biomarkers with the characters of detection, staging and prediction of outcome are highly desirable and being explored in order to make optimized treatment prescription and to improve prognosis for CRC patients.A growing number of researches focus on small non-coding RNA molecules, microRNAs (miRNAs, miRs), which play multiple roles in variety of biological processes, including cancer [5][6][7]. Since 2008, tumor-derived miRNAs were described present stablely in circulating blood, as circulating-based markers for cancer detection [8]. Consider the detection of circulating miRNAs have the advantages of simple, inexpensive and noninvasive, combined with the remarkable stability characteristics of mature miRNAs due to the miRNA-Argonaute-protein complex, the discovery of circulating miRNAs as novel biomarkers for cancer intervention has been widely explored [9,10]. Growing evidences have indicated that aberrant expression of circulating miRNAs has an association with cancer including CRC. The diagnostic and prognostic value of circulating miRNAs exhibited in screening and monitoring, predicting recurrence or metastasis including lymph node, vessel, peritoneal invasion or distant metastasis, stratification by TNM stage or even histological differentiation grade, and few are associated with drug resistance, chemoradiosensitivity, tumor size and gender. This review covers recent researches in circulating miRNAs and their variety potential values correlated with CRC (Figure 1). Experiment FlowExperiment flow for the identification of CRC-related circulating miRNAs apply step-wise strategy. First experiment samples are selected according to dif...

show abstract

“…Recently published reports highlight their oncogenic and prognostic potential. For instance, miR-92a promotes esophageal cancer cell migration and invasion in vitro, and high expression of miR-92a correlates with lymph node metastases and poor overall survival in esophageal squamous cell carcinoma and colorectal carcinoma (44)(45)(46). Similarly, miR-18b overexpression promotes proliferation and loss of cell adhesion, and elevated levels of this miR correlates with reduced relapse-free survival in hepatocellular carcinoma (47).…”

Section: Discussionmentioning

confidence: 99%

miRNA-95 Mediates Radioresistance in Tumors by Targeting the Sphingolipid Phosphatase SGPP1

et al. 2013

View full text Add to dashboard Cite

Radiation resistance poses a major clinical challenge in cancer treatment, but little is known about how microRNA (miR) may regulate this phenomenon. In this study, we used next-generation sequencing to perform an unbiased comparison of miR expression in PC3 prostate cancer cells rendered resistant to fractionated radiation treatment. One miR candidate found to be upregulated by ionizing radiation was miR-95, the enforced expression of which promoted radiation resistance in a variety of cancer cells. miR-95 overexpression recapitulated an aggressive phenotype including increased cellular proliferation, deregulated G 2 -M checkpoint following ionizing radiation, and increased invasive potential. Using combined in silico prediction and microarray expression analyses, we identified and validated the sphingolipid phosphatase SGPP1, an antagonist of sphingosine-1-phosphate signaling, as a target of miR-95 that promotes radiation resistance. Consistent with this finding, cell treatment with FTY720, a clinically approved small molecule inhibitor of S1P signaling, sensitized miR-95 overexpressing cells to radiation treatment. In vivo assays extended the significance of these results, showing that miR-95 overexpression increased tumor growth and resistance to radiation treatment in tumor xenografts. Furthermore, reduced tumor necrosis and increased cellular proliferation were seen after radiation treatment of miR-95 overexpressing tumors compared with control tumors. Finally, miR-95 expression was increased in human prostate and breast cancer specimens compared with normal tissue. Together, our work reveals miR-95 expression as a critical determinant of radiation resistance in cancer cells. Cancer Res; 73(23); 6972-86. Ó2013 AACR.

show abstract

Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer

Cited by 92 publications

References 25 publications

Deregulation of miR‐92a in locally advanced rectal cancer

Deregulation of miR‐92a in locally advanced rectal cancer

Circulating MicroRNAs in Colorectal Cancer

miRNA-95 Mediates Radioresistance in Tumors by Targeting the Sphingolipid Phosphatase SGPP1

Contact Info

Product

Resources

About